Cite

HARVARD Citation

    He, S. et al. (n.d.). A phase II FOLFOX-4 regimen as second-line treatment in advanced biliary tract cancer refractory to gemcitabine/cisplatin. Journal of chemotherapy. pp. 243-247. [Online]. 
  
Back to record